These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11760497)

  • 21. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 23. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [French system of drug surveillance].
    Imbs JL; Castot A; Begaud B; Larousse C; Blayac JP; Alexandre JM
    Bull Acad Natl Med; 1998; 182(7):1383-91; discussion 1392-3. PubMed ID: 9916332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 26. How should we react to adverse drug reactions?
    Ferner RE; Beard K
    Postgrad Med J; 2011 Feb; 87(1024):81-2. PubMed ID: 21303818
    [No Abstract]   [Full Text] [Related]  

  • 27. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases.
    Graham DJ; Smith CR
    Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350
    [No Abstract]   [Full Text] [Related]  

  • 28. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria.
    Hochberg AM; Hauben M
    Clin Pharmacol Ther; 2009 Jun; 85(6):600-6. PubMed ID: 19322165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International monitoring for adverse drug reactions of long latency.
    Fletcher AP; Griffin JP
    Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771
    [No Abstract]   [Full Text] [Related]  

  • 30. [Drug-eruptions].
    Thielen AM; Toutous-Trellu L; Desmeules J
    Rev Med Suisse; 2008 Jul; 4(165):1671-5. PubMed ID: 18767294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A potential competition bias in the detection of safety signals from spontaneous reporting databases.
    Pariente A; Didailler M; Avillach P; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Moore N
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1166-71. PubMed ID: 20848561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
    Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
    Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precautions for proactive surveillance.
    Walker AM; Wise RP
    Pharmacoepidemiol Drug Saf; 2002; 11(1):17-20. PubMed ID: 11998546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advantages of adverse-effect reporting by patients.
    Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug surveillance and adverse reactions to drugs. The literature and importance of historical data].
    Mariani L; Minora T; Ventresca GP
    Clin Ter; 1996 Dec; 147(12):653-72. PubMed ID: 9296925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac adverse effects associated with psychotropic drugs.
    Schmid C; Grohmann R; Engel RR; Rüther E; Kropp S
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S65-9. PubMed ID: 15052516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.